I have been a journalist for more than 25 years and have been specialising in celebrities and showbusiness for most of that time, working on national magazines and newspapers before joining HELLO!

by co-developing drugs and biomarkers,” said Laura Benjamin, OncXerna founder and CEO. Many precision-oncology companies target specific DNA mutations. Only around a fifth of patients benefit ...